Abstract
Hallucinogens comprise a diverse collection of chemicals with multifarious receptor actions in the central nervous system. Preclinical drug screening methods have proven invaluable in the evaluation and characterization of hallucinogen psychopharmacology. Used in concert with structural chemistry and receptor pharmacology methods, preclinical drug discrimination research has informed our current understanding of hallucinogens and the neurochemical receptor mechanisms responsible for their interoceptive stimulus effects. This chapter summarizes the strengths and limitations of drug discrimination as an in vivo drug detection method and offers a brief review of historical and contemporary drug discrimination research with classical hallucinogens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
